Biorez, Inc. has raised $3.5 million in its Series Seed financing and launched a new company website, www.biorez.com.
Biorez Raises $3.5 Million and Launches New Website
1 min read Premium comments
Secondary#biorez#biobrace
Located in New Haven, Connecticut, Biorez is a start-up medical device company. With the additional $3.5 million, Biorez has managed to raise $7 million in financing. Led by New York Angels, this financing round included Connecticut Innovations, Pritzker Vlock Family Office, Brainchild Holdings, and The Vertical Group.
Biorez focuses on tendon and ligament repair using its proprietary BioBrace™ technology. According to its new website, the BioBrace implant is a “biocomposite scaffold that is intended for the reinforcement of soft tissue where weakness exists.” The biocomposite design features a “highly-porous collagen matrix, embedded with bioresorbable polymer microfilaments, to provide an open 3-D biologic scaffold with strength.”
The BioBrace uses its “open porous architecture and biocompatible materials” to facilitate tissue regeneration. Once healed, the implant resorbs. It is intended for use in a variety of tendon and ligament procedures. This includes rotator cuff repair and anterior cruciate ligament (ACL) reconstruction.
Biorez President and CEO Kevin Rocco commented on the BioBrace vision: “Our vision is to help patients return to normal activity sooner and safer.”
Rocco continued, “BioBrace has the potential to create a new category of implant materials known as ‘biocomposites’ that contain both biologic and synthetic materials. This rationally-designed approach creates an opportunity for more durable surgical repairs and faster healing, which we intend to prove clinically.”
Rocco previously served as the director of operations and development at Soft Tissue Regeneration. In November 2016, Soft Tissue Regeneration was rebranded and restarted as Biorez.
All Biorez products are in the development stage. The U.S. Food and Drug Administration (FDA) has not approved the BioBrace for commercial sale or clinical use in the United States.
For OTW’s previous coverage of Biorez, see “ACL Experts Join Biorez Scientific Advisory Board.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.